Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Financial Markets Research: Santarus, Inc.'s Zegerid - Fast-acting Formulation Gaining Momentum in GERD

Published by: Datamonitor

Published: Jun. 30, 2006 - 12 Pages


Table of Contents


SUMMARY
Zegerid revenues expected to reach $229m by 2010


SANTARUS, INC.
Overview
Zegerid


GASTROESOPHAGEAL REFLUX DISEASE
Overview
Proton-pump inhibitors the standard of care for GERD patients
First immediate-release PPI approved in late 2004
Zegerid capsules launced in late March 2006


FACTORS AFFECTING THE POTENTIAL FOR SANTARUS' ZEGERID
Physicians view immediate-release profile as intriguing GERD option
Data in nocturnal GERD patients could further spur Zegerid utilization
Third-party reimbursement tier key to future Zegerid growth
Additional OTC formulations could inhibit future growth in prescription PPI agents
Can Zegerid drive PRN dosing for mild-to-moderate GERD?


DATAMONITOR ZEGERID FORECAST
Novel marketing message and PRN potential should help Zegerid gain niche role
Product profile and PRN potential could make Zegerid an attractive OTC target


APPENDIX
Supplementary data
Datamonitor Healthcare
Disclosure information
Ask the analyst


List of Tables
Table 1: Estimated US Zegerid revenues 2006-2010
Table 2: Estimated US Zegerid revenues 2006-2010

Abstract

Introduction

Following the lackluster 2004 launch of an oral suspension formulation of Santarus' lead product, Zegerid (a fast-acting proton pump inhibitor) much of Santarus' future success is tied to the commercial potential for the recently launched Zegerid oral capsule formulation to drive near-term revenues.

Scope
  • Analyzes the commercial potential for Santarus' Zegerid capsule, the first fast-acting capsule PPI to be approved the US FDA
  • Datamonitor interviewed eight gastroenterologists and primary care physicians familiar with the Zegerid oral capsule in the course of research
Highlights

Despite a very competitive prescription PPI landscape, we believe that Zegerid's rapid absorption profile and data supporting its use in patients with nocturnal breakthrough GERD symptoms should provide Santarus and its marketing partner Otsuka with a relatively compelling marketing message for physicians.

As a result, we forecast US Zegerid revenues slightly ahead of Wall Street consensus.

Reasons to Purchase
  • Understand the commercial potential for Santarus' Zegerid through in-depth analysis based on interviews with leading experts
  • Anticipate likely changes in the future market dynamics for GERD therapies following the likely success of Zegerid


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008